论文部分内容阅读
目的观察分析替米沙坦联合托拉塞米治疗心力衰竭患者的临床疗效。方法 70例心力衰竭患者,按照随机双盲法分为对照组和观察组,每组35例。对照组患者在常规治疗基础上给予托拉塞米治疗,观察组在常规治疗基础上给予替米沙坦联合托拉塞米治疗,比较两组患者的临床治疗效果。结果治疗前两组患者的左室射血分数(LVEF)、脑钠肽(BNP)及同型半胱氨酸(HCY)水平比较差异无统计学意义(P>0.05);治疗后观察组患者LVEF、BNP及HCY水平均明显优于对照组(P<0.05);观察组的治疗总有效率为85.71%,明显高于对照组的60.00%(P<0.05)。结论与单纯托拉塞米比较,采用替米沙坦联合托拉塞米治疗心力衰竭疗效显著,可有效改善心力衰竭症状和心功能,有利于改善预后,值得临床借鉴。
Objective To observe the clinical effect of telmisartan combined with torsemide in patients with heart failure. Methods 70 cases of heart failure patients were divided into control group and observation group according to a randomized double-blind method, 35 cases in each group. Patients in the control group were given torsemide on the basis of routine treatment. The observation group was treated with telmisartan combined with torsemide on the basis of routine treatment. The clinical effects of the two groups were compared. Results There was no significant difference in LVEF, BNP and HCY between the two groups before treatment (P> 0.05). After treatment, LVEF , BNP and HCY levels were significantly better than the control group (P <0.05). The total effective rate in the observation group was 85.71%, which was significantly higher than that in the control group (60.00%, P <0.05). Conclusion Compared with pure torsemide, the treatment of heart failure with telmisartan combined with torsemide has a significant effect, which can effectively improve the symptoms and cardiac function of heart failure, which is beneficial to improve the prognosis and is worthy of clinical reference.